How to Escape the Powder Keg: A Practical Guide to Managing Atherosclerosis

Atherosclerosis cannot be eliminated, but its trajectory can be radically altered. The difference between an atherosclerotic plaque that turns into a powder keg detonating in your fifties and one that remains a stable, dormant deposit for a lifetime is not luck — it is the accumulation of specific, measurable, and largely controllable decisions.

Start With What You Cannot Change — and Measure It

Before addressing lifestyle, the first step is establishing where you actually stand, because atherosclerosis is frequently silent for decades. A coronary artery calcium (CAC) scan is a low-radiation CT scan that directly visualizes calcified plaque in the coronary arteries, giving a concrete score rather than an abstract risk estimate; higher scores correlate with materially higher future cardiovascular risk and directly inform whether preventive treatment such as statin therapy should be intensified. This is particularly valuable for anyone with a family history of early heart disease, since it can detect the disease years before symptoms appear, at a stage when intervention is most effective.

Alongside imaging, two blood tests matter far more than a standard cholesterol panel alone. Lipoprotein(a), or Lp(a), is a largely genetically determined particle that dramatically accelerates plaque formation and instability independent of diet or exercise; it should be checked at least once in adulthood, since it is not part of routine lipid panels but changes clinical management when elevated. High-sensitivity C-reactive protein (hsCRP) measures systemic inflammation, and a level at or above 2 mg/L is now used by major cardiology guidelines as a "risk enhancer" that can justify earlier or more aggressive treatment even when LDL cholesterol looks acceptable.

Lifestyle: The Foundation for the Majority

For most people without a strong genetic predisposition, lifestyle intervention remains the single most powerful lever for slowing atherosclerosis and is supported by every major cardiology body.

• Move daily. At least 150 minutes of moderate aerobic activity per week, ideally spread across most days, measurably reduces blood pressure, improves lipid profiles, and lowers cardiovascular risk.

• Eat to lower inflammation, not just cholesterol. A diet built around vegetables, whole grains, lean protein, and fatty fish — broadly the Mediterranean pattern — reduces both LDL and systemic inflammatory markers, while diets high in refined sugar, and sodium do the opposite.

• Quit tobacco entirely. Smoking is repeatedly identified as the single most modifiable risk factor for accelerating plaque formation and destabilization, and cessation produces measurable risk reduction within months, not years.

• Protect sleep and manage stress. Chronic stress and poor sleep raise blood pressure and inflammatory tone; 7–9 hours of sleep and active stress-reduction practices are now considered core, not optional, components of cardiovascular prevention.

• Maintain a healthy weight. Even modest, sustained weight loss improves blood pressure, glucose regulation, and lipid markers simultaneously, compounding the benefit of the other changes above.

Pharmacology: Non-Negotiable for Elevated Genetic Risk

When genetics load the powder keg — familial hypercholesterolemia, very high LDL, or elevated Lp(a) — lifestyle alone is rarely sufficient, and pharmacological management shifts from optional to essential.

Statins remain first-line therapy, and their benefit extends beyond LDL-lowering: they independently reduce hsCRP and other inflammatory markers, meaning they stabilize plaques through a second mechanism distinct from cholesterol reduction alone. This dual action is precisely why statins improve outcomes even in patients whose LDL is already close to target — the inflammatory reduction matters on its own.

PCSK9 inhibitors were developed to aggressively lower LDL cholesterol in patients who cannot reach targets with statins alone, but they carry a second, increasingly important benefit: they lower Lp(a) by roughly 20–30% in clinical trials, making them one of the few pharmacological tools that meaningfully address this genetically fixed risk factor. In patients with recent acute coronary events and even mildly elevated Lp(a), adding a PCSK9 inhibitor produced a substantial additional reduction in major cardiovascular events beyond statin therapy alone.

Emerging Lp(a)-targeted therapies. Because no drug is yet approved specifically to lower Lp(a) as its primary mechanism, PCSK9 inhibitors are currently used as a partial workaround; a new generation of RNA-based therapies designed to directly suppress Lp(a) production is in late-stage clinical trials and represents the next major advance for patients whose risk is driven primarily by this inherited particle.

Anti-inflammatory options for statin-intolerant patients. For patients who cannot tolerate statins, bempedoic acid and ezetimibe both significantly reduce CRP independent of their LDL-lowering effects, and omega-3 fatty acids show a similar, smaller anti-inflammatory benefit — giving statin-intolerant patients a real path to controlling the inflammatory side of plaque vulnerability.

Aspirin: a mirror of the disease's own dual nature. Atherosclerosis has always had two faces — a slow inflammatory buildup and a sudden thrombotic event when a plaque ruptures — and aspirin is one of the few drugs whose own pharmacodynamics split along exactly this line. Its dominant mechanism is irreversible inhibition of platelet COX-1, blocking thromboxane A2 and preventing the clot that turns a ruptured plaque into a heart attack or stroke; this antiplatelet effect is well established and drives a 20–25% reduction in recurrent events in patients who have already had one. Aspirin also inhibits COX-2 and carries a genuine anti-inflammatory component, but at standard cardiac doses this effect is markedly weaker than its antiplatelet action, since aspirin is roughly 170 times more selective for COX-1. This is why aspirin's benefit is highly stage-dependent: in secondary prevention, after a cardiovascular event has already occurred, its antithrombotic role is decisive and evidence-based. The takeaway is not that aspirin is universally useful, but that its dual pharmacodynamic profile is a genuine pharmacological echo of the disease's own dual nature — and precisely for that reason, it needs to be matched to the right stage, not applied indiscriminately.

Keeping the Fuse Damp: Why Inflammation Control Is a Distinct Goal

Lowering cholesterol and controlling inflammation are related but separate tasks, and treating them as one and the same is a common mistake. A patient can have excellent LDL numbers and still carry high hsCRP, and that combination carries meaningfully elevated risk of death and cardiovascular events compared to patients with low inflammation, regardless of their LDL level. This is the clinical proof behind the "damp fuse" idea: even a well-controlled powder keg can still ignite if the inflammatory environment around the plaque remains hot. Practically, this means asking your physician to check hsCRP specifically, not assuming a normal lipid panel tells the whole story, and treating an elevated hsCRP as a trigger for intensifying either lifestyle intervention or medication rather than leaving it unaddressed.

Keeping the Fuse Damp: Why Inflammation Control Is a Distinct Goal

Lowering cholesterol and controlling inflammation are related but separate tasks, and treating them as one and the same is a common mistake. A patient can have excellent LDL numbers and still carry high hsCRP, and that combination carries meaningfully elevated risk of death and cardiovascular events compared to patients with low inflammation, regardless of their LDL level. This is the clinical proof behind the "damp fuse" idea: even a well-controlled powder keg can still ignite if the inflammatory environment around the plaque remains hot. Practically, this means asking your physician to check hsCRP specifically, not assuming a normal lipid panel tells the whole story, and treating an elevated hsCRP as a trigger for intensifying either lifestyle intervention or medication — statins, bempedoic acid, or dietary anti-inflammatory strategies — rather than leaving it unaddressed.

From Powder Keg to Chronic, Monitored Condition

The strategy that converts atherosclerosis from an unpredictable threat into a manageable chronic condition rests on three combined actions: knowing your actual numbers (CAC score, Lp(a), hsCRP, LDL) rather than assuming risk from age or family history alone; treating the modifiable risk factors — activity, diet, smoking, weight, sleep — as a daily practice rather than a one-time fix; and, when genetics load the risk, using pharmacological tools aggressively and early rather than waiting for a clinical event to justify them.

None of this requires eliminating uncertainty — atherosclerosis will likely accompany most of us through life in some form. What changes with this approach is the odds: a powder keg that is measured, monitored, and kept away from inflammatory sparks behaves nothing like one left in the dark. The choice that remains entirely in your hands is not whether you carry the risk, but how deliberately you manage it.

You can learn more by reading our e-book 

Mykola Iabluchanskyi together with Andriy Yabluchanskiy